Skip to Content

Pediotic (hydrocortisone / neomycin / polymyxin b otic) Disease Interactions

There are 4 disease interactions with Pediotic (hydrocortisone / neomycin / polymyxin b otic):

Major

Neomycin (Otic) (Includes Pediotic) ↔ Perforated Tympanic Membrane

Severe Potential Hazard, High plausibility

Applies to: Perforated Tympanic Membrane

Like other aminoglycosides, neomycin is potentially ototoxic, both to vestibular and to auditory functions. Therapy with neomycin otic preparations should be administered cautiously in patients with chronic otitis media or a perforated tympanic membrane. The risk of ototoxicity may be increased if medication enters the middle ear.

References

  1. "Product Information. Mycifradin (neomycin)." Emerson Laboratories, Texarkana, TX.
Major

Otic Agents (Includes Pediotic) ↔ Perforated Tympanic Membrane

Severe Potential Hazard, High plausibility

Applies to: Perforated Tympanic Membrane, Chronic Otitis Media

The use of medications that are intended for the treatment of otitis externa or other conditions of the external ear canal should generally be avoided, or otherwise approached with caution, in patients with a perforated tympanic membrane due to the risk of toxicity from medication that may get into the middle ear. Caution is also advised in patients with longstanding, chronic otitis media because of the possibility of a perforated tympanic membrane in such patients.

References

  1. "Multum Information Services, Inc. Expert Review Panel"
  2. Behrman R, Kliegman R, Arvin A, Nelson W, eds. "Nelson Textbook of Pediatrics. 15th ed." Philadelphia, PA: W.B. Saunders Company (1996):
Major

Otic Corticosteroids (Includes Pediotic) ↔ Viral Infections

Severe Potential Hazard, High plausibility

Applies to: Herpes Simplex Otitis Externa, Herpes Zoster Otitis Externa

The use of otic preparations containing corticosteroids is contraindicated in patients with viral infections of the external canal including varicella and herpes simplex otitis externa. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. Normally, corticosteroids may be administered with caution provided it is accompanied by appropriate anti-infective agents. However, otic preparations that are currently available lack effective antiviral agents.

References

  1. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Moderate

Topical Aminoglycosides (Includes Pediotic) ↔ Burns

Moderate Potential Hazard, High plausibility

Applies to: Burns - External

Topical aminoglycosides should not be used on serious burns. When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin. Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions. In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.

References

  1. "Product Information. Myciguent (neomycin topical)." Pharmacia and Upjohn, Kalamazoo, MI.

Pediotic (hydrocortisone / neomycin / polymyxin b otic) drug Interactions

There are 20 drug interactions with Pediotic (hydrocortisone / neomycin / polymyxin b otic)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide